HDAC1 Revealed: Tumor Suppressor in ALK+ ALCL
- Post by: fantom
- 22 April 2025
- No Comment
HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy
As a part of my PhD in Gerda Egger’s lab, within the Fantom network, I contributed to a recently published paper in Leukemia entitled “HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy”.
In this study, we investigated the role of HDAC1 and HDAC2 in ALK-positive anaplastic large cell lymphoma (ALCL). Our key findings include:
• HDAC1 and HDAC2 act as tumor suppressors in development of ALK+ ALCL
• Mechanistic insights: Loss of HDAC1 protein or its enzymatic activity led to dysregulation of T cell transcriptional programs and activation of multiple oncogenic signaling cascades, including PDGFRB signaling
• Therapeutic relevance: Despite their tumor suppressive functions, systemic HDAC inhibition with Entinostat significantly delayed lymphoma onset in vivo, highlighting the therapeutic potential of selective HDAC inhibitors in ALCL
These findings challenge the conventional understanding of HDACs as solely oncogenic factors and underscore the need for a nuanced approach to HDAC-targeted therapies in ALK+ ALCL.
Check the full paper here.